Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.

被引：1
|
作者：
Paik, Paul K.
Ahn, Linda Su Hyun
Ginsberg, Michelle S.
Plodkowski, Andrew J.
Kim, Rachel
Doyle, L. Austin
Rudin, Charles M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mt Sinai Med Ctr, Palisades Pk, NJ USA
[3] Greenbaum Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9085
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma
    Zhang, Yongxing
    Fan, Hong
    Fang, Shuo
    Wang, Lin
    Chen, Li
    Jin, Yulin
    Jiang, Wei
    Lin, Zongwu
    Shi, Yu
    Zhan, Cheng
    Wang, Qun
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : 1639 - +
  • [22] KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
    Zhu, Hongyuan
    Yu, Yunfang
    Zheng, Yating
    Xu, Bin
    Zheng, Shaopeng
    Zeng, Fanjun
    Xie, Wenzhuan
    Huang, Luyu
    Li, Fasheng
    Lin, Weihuan
    Liao, Guoqing
    Wu, Shaowei
    Liu, Xinyi
    Huang, Mengli
    Zhou, Haiyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] CANCER RELATED METHYLATION IN KEAP1 ACTIVATE NFE2L2 ACTIVITY AND PROMOTE MALIGNANCY OF CERVICAL CANCER
    Hasimu, A.
    Ma, J.
    Mamtimin, B.
    Yimiti, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 810 - 810
  • [24] Relationship between KEAP1/NFE2L2 pathway activation and radiation resistance in oral cavity cancer.
    Guan, Li
    Cao, Hongbin
    Hui, Angela
    Kwok, Shirley
    Viswanathan, Vignesh
    Nambiar, Dhanya
    Eyben, Rie V.
    Holmes, Brittany
    Kong, Christina
    Diehn, Maximilian
    Quynh-Thu Le
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [25] KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis"
    Mazzotta, Marco
    Marinelli, Daniele
    Maugeri-Sacca, Marcello
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : E87 - E88
  • [26] NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy
    Xu, Xian
    Yang, Yang
    Liu, Xiaoyan
    Cao, Na
    Zhang, Peng
    Zhao, Songhui
    Chen, Donglin
    Li, Li
    He, Yong
    Dong, Xiaowei
    Wang, Kai
    Lin, Hanqing
    Mao, Naiquan
    Liu, Lingxiang
    ONCOLOGIST, 2020, 25 (06): : E955 - E963
  • [27] Understanding Nfe2l2/Keap1-Mediated Drug Resistance In Hepatoblastoma
    Rotari, A.
    Failli, M.
    Cairo, S.
    di Bernardo, D.
    Kappler, R.
    KLINISCHE PADIATRIE, 2023, 235 (03): : 200 - 200
  • [28] Inhibition of SIRT1 promotes ultraviolet B induced cataract via downregulation of the KEAP1/NFE2L2 signaling pathway
    Wu, Feiying
    Xia, Xinyu
    Lei, Ting
    Du, Huiying
    Hua, Hui
    Liu, Wei
    Xu, Bin
    Yang, Tianyao
    JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2023, 245
  • [29] The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity
    Rubens, Jeffrey A.
    Wang, Sabrina Z.
    Price, Antoinette
    Weingart, Melanie F.
    Allen, Sariah J.
    Orr, Brent A.
    Eberhart, Charles G.
    Raabe, Eric H.
    NEURO-ONCOLOGY, 2017, 19 (10) : 1361 - 1371
  • [30] KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
    Binkley, Michael S.
    Jeon, Young-Jun
    Nesselbush, Monica
    Moding, Everett J.
    Nabet, Barzin
    Almanza, Diego S.
    Yoo, Christopher
    Kurtz, David Matthew
    Owen, Susie Grant
    Backhus, Leah Monique
    Berry, Mark F.
    Shrager, Joseph B.
    Ramchandran, Kavitha
    Padda, Sukhmani Kaur
    Das, Millie
    Neal, Joel W.
    Wakelee, Heather A.
    Alizadeh, Ash A.
    Loo, Billy W.
    Diehn, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345